Ontology highlight
ABSTRACT:
SUBMITTER: Stuart RK
PROVIDER: S-EPMC4354261 | biostudies-literature | 2015 Mar
REPOSITORIES: biostudies-literature
Stuart Robert K RK Cripe Larry D LD Maris Michael B MB Cooper Maureen A MA Stone Richard M RM Dakhil Shaker R SR Turturro Francesco F Stock Wendy W Mason James J Shami Paul J PJ Strickland Stephen A SA Costa Luciano J LJ Borthakur Gautam G Michelson Glenn C GC Fox Judith A JA Leavitt Richard D RD Ravandi Farhad F
British journal of haematology 20141117 6
This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m(2) d 1, 8, 15; B: 72 mg/m(2) d 1, 8; C: 72 mg/m(2) or 90 mg/m(2) d 1, 4). The primary endpoint was combined complete remission rate (complete remission [CR] plus CR with incomplete platelet recovery [CRp]). C ...[more]